
STOK Stock Forecast & Price Target
STOK Analyst Ratings
Bulls say
Stoke Therapeutics Inc. has demonstrated a strong financial performance in FY25, with revenues increasing significantly to $184 million, primarily driven by a $165 million upfront payment from a collaboration agreement with Biogen. The company is actively advancing its lead candidate, zorevunersen, showing promising results in its phase I/II studies with substantial seizure reductions in Dravet syndrome patients, which bodes well for its ongoing phase III EMPEROR study. Furthermore, the investment in research and development, reflected by a 55% increase in R&D expenses to $138 million, underscores Stoke's commitment to advancing its innovative RNA medicines targeting haploinsufficiency diseases.
Bears say
The financial outlook for Stoke Therapeutics Inc. is concerning due to significant risks surrounding its intellectual property, notably the potential for key patents to be disputed or not issued, which could hinder market success and negatively impact valuation. The company reported a net loss of $6.9 million for 2025, with an earnings per share of -$0.12, indicating ongoing financial challenges and a lack of profitability anticipated for several years. Additionally, the necessity for raising further capital poses financial risks, as any equity financing could lead to share dilution, further impairing shareholder value.
This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
STOK Analyst Forecast & Price Prediction
Start investing in STOK
Order type
Buy in
Order amount
Est. shares
0 shares